|Day Low/High||8.36 / 8.65|
|52 Wk Low/High||7.37 / 35.65|
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Merrimack Pharmaceuticals Inc , where a total of 582 contracts have traded so far, representing approximately 58,200 underlying shares. That amounts to about 53.7% of MACK's average daily trading volume over the past month of 108,375 shares.
Randomized Phase 2 study accrual raised to 100 patients; data still expected later this year
Members include world-renowned experts in biomarker-defined cancers, bioengineering, drug discovery and clinical development
The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
The Boston firm unveils positive results from its Phase 3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.
Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.
Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the May 19th expiration.
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.
The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.
McKesson, Bristol-Myers and Varian were having a busy morning.
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the September 15th expiration.
The Dow Jones Industrial Average's road to 20,000 has another detour as a selloff in crude spooks the energy sector.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.
Stocks trade mostly lower Monday with the Dow Jones Industrial Average taking a pause in its race toward 20,000.
Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.
Deals, though, weren't the only mover of share prices.
Stock futures mostly lower Monday morning amid a slump in crude oil prices.
The Nasdaq-listed cancer drug developer is up 43% in premarket trading after promising shareholders special dividends worth more than its closing share price on Friday.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.